Direkt zum Inhalt
Merck

A0487

Sigma-Aldrich

Argatroban Monohydrat

≥98% (HPLC)

Synonym(e):

(2R,4R)-1-[(2S)-5-[(Aminoiminomethyl)-amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-chinolinyl)-sulfonyl]-amino]-pentyl]-4-methyl-2-piperidincarbonsäure Monohydrat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
CHF 89.90
25 MG
CHF 325.00

CHF 89.90


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
5 MG
CHF 89.90
25 MG
CHF 325.00

About This Item

Empirische Formel (Hill-System):
C23H36N6O5S · H2O
CAS-Nummer:
Molekulargewicht:
526.65
MDL-Nummer:
UNSPSC-Code:
12352200
NACRES:
NA.77

CHF 89.90


Check Cart for Availability

Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to off-white

Löslichkeit

DMSO: ≥20 mg/mL

Ersteller

Baxter

Lagertemp.

2-8°C

SMILES String

[S](=O)(=O)(NC(CCCNC(=N)N)C(=O)N3[C@H](C[C@@H](CC3)C)C(=O)O)c1c2c(ccc1)CC(CN2)C.O

InChI

1S/C23H36N6O5S.H2O/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19;/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26);1H2/t14-,15?,17?,18-;/m1./s1

InChIKey

AIEZTKLTLCMZIA-LINCPPCXSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Argatroban anticoagulant is synthesized from L-arginine [1] and photodegrades under light exposure.[2]

Anwendung

Argatroban monohydrate has been used as a thrombin-selective inhibitor in the thrombin assay of platelet poor plasma samples[3]. It may be used as a standard in gradient reversed-phase liquid chromatography coupled with high-resolution multistage mass spectrometry (LC/HR-MSn) for photoproducts fragmentation analysis[2] and as a thrombin inhibitor competitive assay with fullerene-based C60 nanoparticle (NPs).[4]

Biochem./physiol. Wirkung

Argatroban has a high affinity[5] and binds to arginine in thrombin active site resulting in steric hindrance for substrate binding.[1] Argatroban is effective in preventing thrombus formation and favors thrombolysis than unfractionated heparin.[1] It is recommended for acute ischemic stroke treatment.[5]
Argatroban is a potent, selective, direct inhibitor of thrombin and a clinical anticoagulant.
Argatroban is a potent, seletive, univalent direct inhibitor of thrombin. It directly inhibits thrombin by binding only to its active site (thus univalent) as compared to Bivalent DTIs (hirudin and analogs) which bind both to the active site and exosite 1.

Leistungsmerkmale und Vorteile

This compound was developed by Baxter. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Arnat Balabiyev et al.
Biomaterials, 277, 121087-121087 (2021-09-04)
Implantation of biomaterials and medical devices in the body triggers the foreign body reaction (FBR) which is characterized by macrophage fusion at the implant surface leading to the formation of foreign body giant cells and the development of the fibrous
Solution-Mediated Phase Transformation of Argatroban: Ternary Phase Diagram, Rate-Determining Step, and Transformation Kinetics
Wang Y, et al.
Industrial & Engineering Chemistry Research, 56(15), 4539-4548 (2017)
Photodegradation of aqueous argatroban investigated by LC/MSn: Photoproducts, transformation processes and potential implications
Secretan PH, et al.
Journal of Pharmaceutical and Biomedical Analysis, 131(29387), 223-232 (2016)
Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model
Yamada K, et al.
Thrombosis Research, 109(1), 55-64 (2003)
Jeremy B Chang et al.
Scientific reports, 6, 29387-29387 (2016-07-22)
A central challenge in designing and administering effective anticoagulants is achieving the proper therapeutic window and dosage for each patient. The Hill coefficient, nH, which measures the steepness of a dose-response relationship, may be a useful gauge of this therapeutic

Artikel

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.